Perigo (PRGO) Q3 2025: OTC Share Climbs 90bps as Strategic Reviews Reshape Portfolio
Perigo’s Q3 saw resilient OTC share gains offset by broad consumption headwinds and shifting portfolio priorities. The company’s 3S strategy—stabilize, streamline, and strengthen—drove operational improvement, but soft demand and underperforming infant formula required a guidance reset and triggered a major business review. With derma cosmetics divestiture and further strategic reviews underway, Perigo is positioning for a leaner, more focused consumer health platform in 2026.
Summary
- OTC Share Expansion Amid Weak Demand: Perigo outpaced declining OTC markets, gaining share in both U.S. and Europe.
- Portfolio Overhaul Accelerates: Strategic reviews of infant formula and oral care signal a sharper consumer health focus.
- Margin Discipline Holds: Cost initiatives and supply chain improvements cushioned profit despite top-line softness.
Performance Analysis
Perigo’s Q3 results reflect a business navigating both acute market softness and internal transformation. Organic net sales declined 4.4%, with global OTC down 1.6% and businesses under review (infant formula, oral care) accounting for a 2.8% drag. Despite these pressures, Perigo posted six straight months of U.S. store brand OTC share gains, up 90 basis points in the latest 13 weeks, and key European brands delivered five months of dollar share growth amid category contraction.
Gross profit and margin fell year-over-year, primarily due to lower sales and mix shift toward lower-margin store brands. However, operating margin improved sequentially by 180 basis points, buoyed by cost management and the non-repeat of prior quarter scrap expenses. Year-to-date, organic operating income grew 13%, and EPS rose 21% (27% organically), underscoring the impact of supply chain reinvention and Project Energize, which delivered $163 million in annual savings.
- Top-Line Weakness Concentrated in Under-Review Segments: Infant formula and oral care underperformed, prompting a $100 million revenue impact and strategic reassessment.
- Supply Chain Reinvention Delivers: $150–$200 million benefit target for 2025 on track, with cost savings mitigating margin pressure.
- AMP Investment Reallocation: Targeted advertising and promotional spend generated $30 million in incremental sales, validating focused brand support.
The portfolio’s resilience in core OTC contrasts with volatility in nutrition and oral care, highlighting the importance of ongoing strategic realignment.
Executive Commentary
"Perigo has delivered sustained share gains and advanced key initiatives under our 3S plan to stabilize, streamline, and to strengthen. These efforts are enabling us to navigate the challenging landscape while making steady progress on our strategic priorities and reinforcing our long-term value proposition."
Patrick Lockwood-Taylor, President and Chief Executive Officer
"Margins are holding through discipline, cost management, and the benefits of our efficiency programs. We remain committed to returning cash to shareholders while reducing leverage supported by the pending dermacosmetic divestiture."
Eduardo Bezerra, Chief Financial Officer
Strategic Positioning
1. OTC Store Brand Leadership
Perigo’s U.S. store brand OTC business continues to outperform national brands, gaining volume and dollar share in five of seven categories. The company’s multi-price point model—offering products at several value tiers—has proven resilient as consumers trade down amid inflation. This share momentum is reinforced by new distribution wins and consumer switching from more expensive national brands.
2. Portfolio Streamlining and Divestiture
The sale of the derma cosmetics business is on track for Q1 2026 closing, with proceeds earmarked for debt reduction. In parallel, Perigo has launched strategic reviews of both the infant formula and oral care businesses, pausing a planned $240 million formula investment. This signals a decisive move toward focusing resources on faster-growing, higher-margin consumer health segments.
3. Efficiency and Cost Programs
Supply chain reinvention and Project Energize have delivered above-target savings, supporting margin stability even as revenue fell. These programs focus on manufacturing optimization, procurement, and logistics, and are expected to yield $150–$200 million in annualized benefits by year-end.
4. Innovation and Brand Investment
Perigo is scaling new brand-building capabilities and an improved innovation process, enabling faster rollout of new molecules and formats across markets. Targeted AMP (Advertising, Merchandising, Promotion) investments in key brands generated measurable sales upside, and further innovation is expected to accelerate share gains in 2026.
5. Strategic Retail Partnerships
Deepening relationships with major retailers is a core differentiator. Perigo’s ability to support retail partners with store brand solutions during consumer trade-down cycles has strengthened its negotiating position and shelf presence, particularly as retailers seek to expand private label offerings.
Key Considerations
This quarter marks a critical inflection point for Perigo’s portfolio and capital allocation strategy. The company is actively shifting resources toward core OTC, leveraging operational efficiency, and preparing for a post-divestiture landscape.
Key Considerations:
- Infant Formula Strategic Review: The business is stabilized but faces slow share recovery and increased competition from imports, leading to a full review and capital redeployment.
- Tariff and Cost Pressures: Tariff-related costs of $40–$50 million are being mitigated through price increases and sourcing adjustments, but margin risk persists into 2026.
- AMP and Innovation Payback: Focused brand investments are generating incremental sales, validating the strategy of concentrating spend on high-performing assets.
- Balance Sheet and Leverage: Year-end net debt/EBITDA is now expected at 3.8x (vs. 3.5x prior), with deleveraging dependent on successful divestitures and cash flow execution.
Risks
Key risks include continued broad OTC consumption softness, slow infant formula share recovery, and execution risk around portfolio divestitures. Tariff volatility and input cost inflation remain ongoing threats to gross margin, while competitive intensity in both branded and store brand categories could pressure share gains if consumer trends shift. The company’s ability to execute on strategic reviews and reallocate capital efficiently will be critical for long-term value creation.
Forward Outlook
For Q4, Perigo guided to:
- Global OTC organic growth of flat to 1%
- Nutrition (infant formula) sales down year-over-year, reflecting lower contract volumes and tough comps
For full-year 2025, management lowered guidance:
- Organic net sales growth of minus 2.5%
- Gross margin of approximately 39%
- Operating margin affirmed at 15%
- EPS range of $2.70 to $2.80 (5–9% YoY growth)
Management cited:
- Soft OTC category demand in both U.S. and Europe
- Delayed infant formula share recovery and competitive import pressure
Takeaways
Perigo’s Q3 underscores the tension between operational discipline and top-line volatility as the company pivots to a leaner consumer health model.
- OTC Share Gains Outpace Market Decline: Perigo’s ability to grow share in a shrinking category demonstrates brand and execution strength, but cannot fully offset broad consumption headwinds.
- Portfolio Realignment Signals Strategic Discipline: The decision to review and potentially divest underperforming segments marks a commitment to focus and capital efficiency.
- 2026 Hinges on Execution and Demand Recovery: Investors should watch for normalization in OTC consumption, successful portfolio streamlining, and the impact of innovation and retailer partnerships on future growth.
Conclusion
Perigo is leveraging cost control and share gains to weather a tough demand environment, but its future will be shaped by the outcome of strategic reviews and the ability to reaccelerate growth in core OTC. Portfolio focus, operational agility, and capital discipline will define its path into 2026.
Industry Read-Through
Perigo’s results reflect broader consumer health trends, with OTC category softness and private label share gains as retailers and consumers seek value. The shift toward portfolio streamlining and divestiture of non-core segments is emblematic of industry-wide moves to shed low-growth or capital-intensive businesses. Supply chain efficiency and targeted brand investment are increasingly critical as margin levers, while tariff and input cost volatility remain sector-wide risks. Competitors with strong retailer partnerships and flexible cost structures will be best positioned to capture share as demand normalizes.